What is the treatment of bronchitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Bronchitis

Critical Distinction: Acute vs. Chronic Bronchitis

The treatment of bronchitis depends entirely on whether you are dealing with acute bronchitis (viral illness lasting <3 weeks) or chronic bronchitis (productive cough for ≥3 months/year for ≥2 consecutive years), as these require fundamentally different management approaches. 1, 2


Acute Bronchitis Management

First-Line Treatment

For acute bronchitis in immunocompetent adults, use albuterol (short-acting β-agonist) as first-line therapy to reduce cough duration and severity, NOT antibiotics. 1

  • Albuterol reduces cough presence by approximately 50% at 7 days and should be offered to patients with wheezing or bothersome cough 1
  • Consider β2-agonist bronchodilators specifically in patients with wheezing accompanying the cough 2

What NOT to Do

Do NOT routinely prescribe antibiotics for uncomplicated acute bronchitis - they reduce cough by only 0.5 days while exposing patients to adverse effects including allergic reactions, nausea, and Clostridium difficile infection 3, 1, 2, 4, 5

  • Viruses cause >90% of acute bronchitis cases 4
  • Purulent sputum does NOT indicate bacterial infection and should not trigger antibiotic use 2, 4
  • Antibiotics are only indicated if pertussis is suspected or if bacterial superinfection develops 3, 2, 4

Symptomatic Management

  • Antitussives (dextromethorphan or codeine) provide modest short-term relief and can be offered for symptomatic control 1, 2
  • Low-cost interventions like eliminating environmental triggers and vaporized air treatments are reasonable 1
  • Do NOT use routine chest physiotherapy, expectorants, or mucokinetic agents - they lack proven benefit 2

Diagnostic Approach

  • No routine investigations needed - do not order chest x-rays, sputum cultures, viral PCR, or inflammatory markers for uncomplicated cases 2
  • Rule out pneumonia if patient has heart rate >100 bpm, respiratory rate >24 breaths/min, temperature >38°C, or focal chest findings 2
  • Consider pertussis if cough persists >2 weeks with paroxysmal features, whooping, or post-tussive emesis 3, 5

Patient Education

Tell patients cough typically lasts 10-14 days after the visit - setting realistic expectations reduces unnecessary follow-up and antibiotic requests 1


Chronic Bronchitis Management

Bronchodilator Therapy (Cornerstone of Treatment)

For stable chronic bronchitis, use short-acting β-agonists to control bronchospasm and relieve dyspnea, which may also reduce chronic cough. 3, 1

Ipratropium bromide should be offered to improve cough - studies show patients cough fewer times with less severity and decreased sputum volume 3, 1

  • Tiotropium bromide (long-acting anticholinergic) is FDA-approved for long-term maintenance treatment of bronchospasm in COPD including chronic bronchitis 6
  • Theophylline can be considered for chronic cough control but requires careful monitoring for complications due to side effects and drug interactions 3, 1

Corticosteroids

  • Do NOT use corticosteroids routinely in stable chronic bronchitis 3
  • Combined long-acting β-agonist plus inhaled corticosteroid reduces exacerbation rates and cough in patients with severe airflow obstruction (FEV1 <50%) 3

What NOT to Do

  • Do NOT use routine chest physiotherapy or postural drainage - clinical benefits are unproven 3
  • Do NOT use prophylactic antibiotics in stable patients 3
  • Do NOT use expectorants - beneficial effects have not been proven 3

Acute Exacerbation of Chronic Bronchitis

When to Treat with Antibiotics

Reserve antibiotics for patients with ≥1 key symptom (increased dyspnea, sputum production, or sputum purulence) PLUS ≥1 risk factor: 7

Risk factors:

  • Age ≥65 years 7
  • FEV1 <50% predicted 7
  • ≥4 exacerbations in 12 months 7
  • Comorbidities present 7

Antibiotic Selection

For moderate exacerbations: newer macrolide, extended-spectrum cephalosporin, or doxycycline 7

For severe exacerbations: high-dose amoxicillin/clavulanate or respiratory fluoroquinolone 7, 8

Bronchodilator Therapy During Exacerbations

Use short-acting β-agonists or anticholinergic bronchodilators; if no prompt response, add the other agent after maximizing the first 3

  • Do NOT use theophylline for acute exacerbations 3

Corticosteroids

Oral corticosteroids (or IV in severe cases) are useful for acute exacerbations, though effects on cough specifically have not been systematically evaluated 3


Common Pitfalls to Avoid

  • Prescribing antibiotics for uncomplicated acute bronchitis despite overwhelming evidence of lack of benefit 3, 1, 2
  • Failing to distinguish acute bronchitis from chronic bronchitis exacerbations - they require different approaches 1, 2
  • Not providing realistic expectations about 2-3 week cough duration, leading to unnecessary follow-up 1, 4, 5
  • Overlooking bronchodilator therapy which has demonstrated clear benefit in both acute and chronic bronchitis 1, 2
  • Using purulent sputum as justification for antibiotics - this does not indicate bacterial infection 2, 4

References

Guideline

Acute Bronchitis Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Acute Bronchitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Diagnosis and treatment of acute bronchitis.

American family physician, 2010

Research

Acute Bronchitis.

American family physician, 2016

Research

Infectious exacerbations of chronic bronchitis: diagnosis and management.

The Journal of antimicrobial chemotherapy, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.